← Back to Clinical Trials
Recruiting NCT07073248

NCT07073248 Effects of Intermitted Theta Burst Stimulation (iTBS) on Motor Recovery of Upper Extremity in Chronic Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07073248
Status Recruiting
Phase
Sponsor Danderyd Hospital
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 48 participants
Start Date 2025-11
Primary Completion 2030-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Intermittent Theta Burst StimulationSham Intermittent Theta Burst Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 48 participants in total. It began in 2025-11 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the effects and clinical feasibility of non-invasive brain stimulation protocols, specifically intermittent Theta Burst Stimulation, as part of rehabilitation interventions for motor recovery of upper extremity in the chronic phase after stroke. It also seeks to explore the underlying mechanisms by investigating changes of functional and structural brain networks.

Eligibility Criteria

Inclusion Criteria: * Age over 18 * Chronic stroke (\>6 months) * Residual hemiparesis FM-UE\>17 Exclusion Criteria: * Metal implants * Epilepsy/seizures * Pregnancy * Claustrophobia (related to MRIs exams) * Severe cognitive impairment * Untreated or unstable depression/anxiety * Other disabilities prohibiting intensive physical training

Contact & Investigator

Central Contact

Susanne Palmcrantz, PhD, Associate Professor

✉ susanne.palmcrantz@ki.se

📞 004681235000

Principal Investigator

Susanne Palmcrantz, PhD, Associate Professor

PRINCIPAL INVESTIGATOR

Dep of Clinical Sciences, Karolinska Institutet

Frequently Asked Questions

Who can join the NCT07073248 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07073248 currently recruiting?

Yes, NCT07073248 is actively recruiting participants. Contact the research team at susanne.palmcrantz@ki.se for enrollment information.

Where is the NCT07073248 trial being conducted?

This trial is being conducted at Stockholm, Sweden.

Who is sponsoring the NCT07073248 clinical trial?

NCT07073248 is sponsored by Danderyd Hospital. The principal investigator is Susanne Palmcrantz, PhD, Associate Professor at Dep of Clinical Sciences, Karolinska Institutet. The trial plans to enroll 48 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology